Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers

We previously reported the safety and efficacy of low dose BaP [Bezafibrate (Bez) and Medroxyprogesterone acetate (MPA)] in 20 acute myeloid leukaemia (AML) patients for whom chemotherapy was not an option. This study provided evidence that BaP had anti-AML activity and improved haemopoiesis; absenc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Contemp Clin Trials Commun
Main Authors: Murray, Jim, Pratt, Guy, Jacob, Abe, Clark, Fiona, Blundred, Rachel, Fox, Sonia, Bishop, Rebecca, Wheatley, Keith, Khanim, Farhat, Bunce, Chris, Drayson, Mark
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6463739/
https://ncbi.nlm.nih.gov/pubmed/31011660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.conctc.2019.100361
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados